154 related articles for article (PubMed ID: 31171545)
1. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
[TBL] [Abstract][Full Text] [Related]
2. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
Cartron G; Zhao-Yang L; Baudard M; Kanouni T; Rouillé V; Quittet P; Klein B; Rossi JF
J Clin Oncol; 2008 Jun; 26(16):2725-31. PubMed ID: 18427151
[TBL] [Abstract][Full Text] [Related]
3. Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma.
Kolstad A; Kumari S; Walczak M; Madsbu U; Hagtvedt T; Bogsrud TV; Kvalheim G; Holte H; Aurlien E; Delabie J; Tierens A; Olweus J
Blood; 2015 Jan; 125(1):82-9. PubMed ID: 25293773
[TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of immunotherapy with mitumprotimut-T (Id-KLH) and GM-CSF following rituximab in follicular B-cell lymphoma.
Koç ON; Redfern C; Wiernik PH; Rosenfelt F; Winter JN; Carter WD; Gold DP; Stewart ME; Ghalie RG; Bender JF
J Immunother; 2010; 33(2):178-84. PubMed ID: 20145546
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine.
Lapenta C; Donati S; Spadaro F; Lattanzi L; Urbani F; Macchia I; Sestili P; Spada M; Cox MC; Belardelli F; Santini SM
Cancer Immunol Immunother; 2019 Nov; 68(11):1791-1804. PubMed ID: 31620858
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
[TBL] [Abstract][Full Text] [Related]
7. Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
Freedman A; Neelapu SS; Nichols C; Robertson MJ; Djulbegovic B; Winter JN; Bender JF; Gold DP; Ghalie RG; Stewart ME; Esquibel V; Hamlin P
J Clin Oncol; 2009 Jun; 27(18):3036-43. PubMed ID: 19414675
[TBL] [Abstract][Full Text] [Related]
8. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.
Jung SH; Lee HJ; Lee YK; Yang DH; Kim HJ; Rhee JH; Emmrich F; Lee JJ
Oncotarget; 2017 Jun; 8(25):41538-41548. PubMed ID: 28088784
[TBL] [Abstract][Full Text] [Related]
9. Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma.
Cox MC; Lapenta C; Santini SM
Cancer Immunol Immunother; 2020 Jun; 69(6):913-925. PubMed ID: 32322910
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
11. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma: a single institution study.
Belhadj K; Delfau-Larue MH; Elgnaoui T; Beaujean F; Beaumont JL; Pautas C; Gaillard I; Kirova Y; Allain A; Gaulard P; Farcet JP; Reyes F; Haioun C
Ann Oncol; 2004 Mar; 15(3):504-10. PubMed ID: 14998857
[TBL] [Abstract][Full Text] [Related]
12. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.
Alfaro C; Perez-Gracia JL; Suarez N; Rodriguez J; Fernandez de Sanmamed M; Sangro B; Martin-Algarra S; Calvo A; Redrado M; Agliano A; Gonzalez A; Rodriguez I; Bolaños E; Hervás-Stubbs S; Perez-Calvo J; Benito A; Peñuelas I; Vigil C; Richter J; Martinez-Forero I; Melero I
J Immunol; 2011 Dec; 187(11):6130-42. PubMed ID: 22048768
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic activity of ex-vivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients.
Tyrinova TV; Leplina OY; Mishinov SV; Tikhonova MA; Shevela EY; Stupak VV; Pendyurin IV; Shilov AG; Alyamkina EA; Rubtsova NV; Bogachev SS; Ostanin AA; Chernykh ER
Cell Immunol; 2013; 284(1-2):146-53. PubMed ID: 23973877
[TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells generated in the presence of granulocyte-macrophage colony-stimulating factor and IFN-alpha are potent inducers of HIV-specific CD8 T cells.
Carbonneil C; Aouba A; Burgard M; Cardinaud S; Rouzioux C; Langlade-Demoyen P; Weiss L
AIDS; 2003 Aug; 17(12):1731-40. PubMed ID: 12891059
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
[TBL] [Abstract][Full Text] [Related]
17. Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.
Morschhauser F; Marlton P; Vitolo U; Lindén O; Seymour JF; Crump M; Coiffier B; Foà R; Wassner E; Burger HU; Brennan B; Mendila M
Ann Oncol; 2010 Sep; 21(9):1870-1876. PubMed ID: 20157180
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
19. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a.
Davis TA; Maloney DG; Grillo-López AJ; White CA; Williams ME; Weiner GJ; Dowden S; Levy R
Clin Cancer Res; 2000 Jul; 6(7):2644-52. PubMed ID: 10914705
[TBL] [Abstract][Full Text] [Related]
20. NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.
Lapenta C; Donati S; Spadaro F; Castaldo P; Belardelli F; Cox MC; Santini SM
J Immunol; 2016 Aug; 197(3):795-806. PubMed ID: 27357153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
